These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 38945975)
1. Stabilization of EREG via STT3B-mediated N-glycosylation is critical for PDL1 upregulation and immune evasion in head and neck squamous cell carcinoma. Xu S; Wang H; Zhu Y; Han Y; Liu L; Zhang X; Hu J; Zhang W; Duan S; Deng J; Zhang Z; Liu S Int J Oral Sci; 2024 Jul; 16(1):47. PubMed ID: 38945975 [TBL] [Abstract][Full Text] [Related]
2. EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy. Liu S; Wang Y; Han Y; Xia W; Zhang L; Xu S; Ju H; Zhang X; Ren G; Liu L; Ye W; Zhang Z; Hu J Theranostics; 2020; 10(23):10589-10605. PubMed ID: 32929368 [No Abstract] [Full Text] [Related]
3. PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy. Xu Y; Gao Z; Hu R; Wang Y; Wang Y; Su Z; Zhang X; Yang J; Mei M; Ren Y; Li M; Zhou X J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34697216 [TBL] [Abstract][Full Text] [Related]
4. The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation. Yu D; Liu X; Han G; Liu Y; Zhao X; Wang D; Bian X; Gu T; Wen L Cell Commun Signal; 2019 Dec; 17(1):173. PubMed ID: 31881947 [TBL] [Abstract][Full Text] [Related]
5. Modulation of PD‑L1 expression by standard therapy in head and neck cancer cell lines and exosomes. Affolter A; Liebel K; Tengler L; Seiz E; Tiedtke M; Azhakesan A; Schütz J; Theodoraki MN; Kern J; Ruder AM; Fleckenstein J; Weis CA; Bieback K; Kramer B; Lammert A; Scherl C; Rotter N; Ludwig S Int J Oncol; 2023 Sep; 63(3):. PubMed ID: 37503786 [TBL] [Abstract][Full Text] [Related]
6. PD‑L1 promotes head and neck squamous cell carcinoma cell growth through mTOR signaling. Zheng A; Li F; Chen F; Zuo J; Wang L; Wang Y; Chen S; Xiao B; Tao Z Oncol Rep; 2019 May; 41(5):2833-2843. PubMed ID: 30864729 [TBL] [Abstract][Full Text] [Related]
7. Upregulated glycolysis correlates with tumor progression and immune evasion in head and neck squamous cell carcinoma. Takahashi H; Kawabata-Iwakawa R; Ida S; Mito I; Tada H; Chikamatsu K Sci Rep; 2021 Sep; 11(1):17789. PubMed ID: 34493792 [TBL] [Abstract][Full Text] [Related]
8. The Reversal of Immune Exclusion Mediated by Tadalafil and an Anti-tumor Vaccine Also Induces PDL1 Upregulation in Recurrent Head and Neck Squamous Cell Carcinoma: Interim Analysis of a Phase I Clinical Trial. Weed DT; Zilio S; Reis IM; Sargi Z; Abouyared M; Gomez-Fernandez CR; Civantos FJ; Rodriguez CP; Serafini P Front Immunol; 2019; 10():1206. PubMed ID: 31214178 [TBL] [Abstract][Full Text] [Related]
9. CircKRT1 drives tumor progression and immune evasion in oral squamous cell carcinoma by sponging miR-495-3p to regulate PDL1 expression. Yang Z; Chen W; Wang Y; Qin M; Ji Y Cell Biol Int; 2021 Jul; 45(7):1423-1435. PubMed ID: 33675276 [TBL] [Abstract][Full Text] [Related]
10. Blocking EREG/GPX4 Sensitizes Head and Neck Cancer to Cetuximab through Ferroptosis Induction. Jehl A; Conrad O; Burgy M; Foppolo S; Vauchelles R; Ronzani C; Etienne-Selloum N; Chenard MP; Danic A; Dourlhes T; Thibault C; Schultz P; Dontenwill M; Martin S Cells; 2023 Feb; 12(5):. PubMed ID: 36899869 [TBL] [Abstract][Full Text] [Related]
11. Expression level of PD-L1 is involved in ALDH1A1-mediated poor prognosis in patients with head and neck squamous cell carcinoma. Zhou AL; Wang X; Yu W; Yang L; Wei F; Sun Q; Wang Y; Kou F; Dong R; Ren X; Zhang X Pathol Res Pract; 2020 Sep; 216(9):153093. PubMed ID: 32825960 [TBL] [Abstract][Full Text] [Related]
12. Epiregulin reprograms cancer-associated fibroblasts and facilitates oral squamous cell carcinoma invasion via JAK2-STAT3 pathway. Wang Y; Jing Y; Ding L; Zhang X; Song Y; Chen S; Zhao X; Huang X; Pu Y; Wang Z; Ni Y; Hu Q J Exp Clin Cancer Res; 2019 Jun; 38(1):274. PubMed ID: 31234944 [TBL] [Abstract][Full Text] [Related]
13. Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage. Hira-Miyazawa M; Nakamura H; Hirai M; Kobayashi Y; Kitahara H; Bou-Gharios G; Kawashiri S Int J Oncol; 2018 Feb; 52(2):379-388. PubMed ID: 29345283 [TBL] [Abstract][Full Text] [Related]
14. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma. Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178 [TBL] [Abstract][Full Text] [Related]
15. Protein kinase D3 regulates the expression of the immunosuppressive protein, PD‑L1, through STAT1/STAT3 signaling. Cui B; Chen J; Luo M; Wang L; Chen H; Kang Y; Wang J; Zhou X; Feng Y; Zhang P Int J Oncol; 2020 Apr; 56(4):909-920. PubMed ID: 32319563 [TBL] [Abstract][Full Text] [Related]
16. Metabolic landscape of head and neck squamous cell carcinoma informs a novel kynurenine/Siglec-15 axis in immune escape. Zhang XY; Shi JB; Jin SF; Wang RJ; Li MY; Zhang ZY; Yang X; Ma HL Cancer Commun (Lond); 2024 Jun; 44(6):670-694. PubMed ID: 38734931 [TBL] [Abstract][Full Text] [Related]
17. SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling. Barzegar M; Ma S; Zhang C; Chen X; Gu Y; Shang C; Jiang X; Yang J; Nathan CA; Yang S; Huang S Br J Cancer; 2017 Oct; 117(8):1154-1163. PubMed ID: 28873083 [TBL] [Abstract][Full Text] [Related]
18. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). Cohen EEW; Bell RB; Bifulco CB; Burtness B; Gillison ML; Harrington KJ; Le QT; Lee NY; Leidner R; Lewis RL; Licitra L; Mehanna H; Mell LK; Raben A; Sikora AG; Uppaluri R; Whitworth F; Zandberg DP; Ferris RL J Immunother Cancer; 2019 Jul; 7(1):184. PubMed ID: 31307547 [TBL] [Abstract][Full Text] [Related]
19. Blockade of adenosine A2A receptor enhances CD8 Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285 [TBL] [Abstract][Full Text] [Related]